NCT05462717 2026-04-08
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
Revolution Medicines, Inc.
Laval University
National Institutes of Health Clinical Center (CC)
Cybrexa Therapeutics